AcusMu Medtech Co. Ltd
Update：2026/11/10
Industries
Main Industry
Health Care
Main Product/Service
Microneedle Patch. AcusMu Medtech Co. Ltd (Acus: Needle, Mu: Micro in Latin) is a professional medical technology company specializing in transdermal delivery. Our microneedle technology can effectively deliver functional ingredients through the skin and into the human body. Leveraging precise manufacturing processes and proprietary formulations, we transform cosmetics, skincare products, and pharmaceuticals into convenient and comfortable transdermal delivery products. In our initial startup phase, we entered the market through beauty and skincare products, first developing three targeted skincare products—anti-acne, spot-fading, and anti-wrinkle—to overcome the bottleneck of conventional commercial skincare products, where functional ingredients fail to be effectively absorbed through the skin.
The content above was translated by Ai
Founded Year
2022
Unified Business No.
90144886
Status
Active
Number of Employees
2
Total Paid-in
Capital
2,153,505 (NT$)
Location of Company
Taiwan
, Taipei City
Overseas Development
United States of America
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Microneedle technology was listed as one of the top ten emerging technologies of 2020 by the American monthly magazine *Scientific American*, possessing novel innovation and poised to exert a significant impact in the future. Our company was established in May 2022 as a technology startup spun off from the research and development achievements of National Taipei University of Technology. The core technology and patented formulas originate from the years of research and development results of Professor Kuo-Yuan Hwa's team at National Taipei University of Technology.
Our microneedle technology can effectively deliver functional ingredients through the skin into the human body, overcoming the bottleneck of traditional transdermal delivery's inability to penetrate the epidermal barrier. The company's founders and team recognized the future market potential of microneedle technology. Coupled with early-stage investments from external investors and the participation of dermatologists in clinical testing, this inspired the motivation to start the business.
During the early stages of our venture, we completed laboratory pilot production, engineering verification, and clinical validation. In addition to being selected for the Ministry of Economic Affairs' 2023 SelectUSA subsidy program, we also received the Taipei City Industry Development Entrepreneurship Subsidy.
Our mission is to utilize our proprietary formulas and precise manufacturing processes to transform cosmetics and pharmaceuticals into convenient, comfortable, portable, easy-to-store, and highly efficient transdermal delivery products in a convenient and comfortable manner.
Our microneedle technology can effectively deliver functional ingredients through the skin into the human body, overcoming the bottleneck of traditional transdermal delivery's inability to penetrate the epidermal barrier. The company's founders and team recognized the future market potential of microneedle technology. Coupled with early-stage investments from external investors and the participation of dermatologists in clinical testing, this inspired the motivation to start the business.
During the early stages of our venture, we completed laboratory pilot production, engineering verification, and clinical validation. In addition to being selected for the Ministry of Economic Affairs' 2023 SelectUSA subsidy program, we also received the Taipei City Industry Development Entrepreneurship Subsidy.
Our mission is to utilize our proprietary formulas and precise manufacturing processes to transform cosmetics and pharmaceuticals into convenient, comfortable, portable, easy-to-store, and highly efficient transdermal delivery products in a convenient and comfortable manner.
The content above was translated by Ai
